drugset / Trial / NCT06825728

Metoprolol in Patients With HFrEF and COPD

NCT06825728

Phase 4 Not yet recruiting 311 enrolled Xiangya Hospital of Central South University
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of the clinical trial was to see if Metoprolol was effective in treating patients with heart failure and chronic obstructive pulmonary disease. It will also learn about the safety of Metoprolol. The main questions it aims to answer are: Did Metoprolol reduce the frequency of all-cause deaths and re-hospitalizations in subjects? What medical problems do participants experience after taking Metoprolol? The researchers will compare different doses of Metoprolol to see the best dose for Metoprolol. Participants will: Take Metoprolol 23.75mg/ day or the maximum tolerable dose of Metoprolol daily for 24 months. Regular outpatient follow-up visits to the research center. Their symptoms and Metoprolol dosage were recorded.

Timeline

Start
2025-02
Primary completion
2028-02
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified 23.75 mg